Barclays PLC set a GBX 6,300 ($84.72) target price on AstraZeneca plc (LON:AZN) in a report published on Wednesday, September 13th. The firm currently has a buy rating on the biopharmaceutical company’s stock.
Several other brokerages have also weighed in on AZN. Liberum Capital reiterated a buy rating and set a GBX 5,500 ($73.96) price target on shares of AstraZeneca plc in a report on Tuesday, May 23rd. Deutsche Bank AG reiterated a buy rating on shares of AstraZeneca plc in a report on Monday, May 22nd. Berenberg Bank raised their price target on AstraZeneca plc from GBX 5,670 ($76.25) to GBX 5,850 ($78.67) and gave the company a buy rating in a research report on Wednesday, May 17th. Kepler Capital Markets restated a buy rating and set a GBX 5,500 ($73.96) target price on shares of AstraZeneca plc in a research note on Monday, June 5th. Finally, Morgan Stanley reiterated a buy rating on shares of AstraZeneca plc in a report on Tuesday, June 6th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Hold and an average target price of GBX 5,111.27 ($68.74).
AstraZeneca plc (LON:AZN) traded up 0.94% during mid-day trading on Wednesday, reaching GBX 4955.00. The company’s stock had a trading volume of 1,662,068 shares. The firm’s market cap is GBX 62.73 billion. The stock’s 50 day moving average is GBX 4,574.46 and its 200 day moving average is GBX 4,884.61. AstraZeneca plc has a one year low of GBX 3,996.00 and a one year high of GBX 5,520.00.
TRADEMARK VIOLATION WARNING: This report was originally published by BBNS and is the sole property of of BBNS. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://baseballnewssource.com/markets/astrazeneca-plc-azn-pt-set-at-gbx-6300-by-barclays-plc/1642353.html.
The firm also recently declared a dividend, which was paid on Monday, September 11th. Stockholders of record on Thursday, August 10th were paid a dividend of GBX 68.90 ($0.93) per share. The ex-dividend date of this dividend was Thursday, August 10th. This represents a dividend yield of 1.35%.
In other AstraZeneca plc news, insider Nazneen Rahman bought 39 shares of the firm’s stock in a transaction that occurred on Thursday, July 27th. The stock was acquired at an average price of GBX 4,370 ($58.77) per share, with a total value of £1,704.30 ($2,291.96).
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with our FREE daily email newsletter.